Patents Examined by Andrea McCollum
-
Patent number: 9670277Abstract: This application discloses ophthalmic formulations and methods for treating inflammatory disease and conditions of the ocular surface with one or more C—C chemokine receptor type 7 (CCR7) antagonists. The compositions may be formulated for subconjunctival or topical administration to the eye and are effective in the treatment of inflammatory disease and conditions of the ocular surface.Type: GrantFiled: February 24, 2012Date of Patent: June 6, 2017Assignee: The Schepens Eye Reasearch Institute, Inc.Inventors: Reza Dana, Daniel Saban
-
Patent number: 9662395Abstract: The invention relates to use of non-surfactant compounds including, for example, polyoxyethylene (POE) sorbitans and polyethylene glycols (PEGs), for stabilizing protein-containing formulations and for the prevention of aggregation of proteins in such formulations.Type: GrantFiled: September 21, 2012Date of Patent: May 30, 2017Assignee: GENENTECH, INC.Inventors: Junyan Ji, Jun Liu, Yuchang John Wang
-
Patent number: 9657110Abstract: The present invention provides a polypeptides capable of modulating tissue transglutaminase-induced cell behavior wherein the polypeptide comprises or consists of either (a) the amino acid sequence of a heparin-binding site of a tissue transglutaminase, or a functional fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof or (b) an antibody capable of binding to a heparin-binding site of a tissue transglutaminase, or an antigen-binding fragment or derivative thereof. In one embodiment, the heparin-binding site of a tissue transglutaminase comprises or consists of an amino acid sequence of SEQ ID NO: 1, The invention further provides medical uses of the polypeptides of the invention and methods of treatment using the same.Type: GrantFiled: April 30, 2012Date of Patent: May 23, 2017Assignee: ASTON UNIVERSITYInventors: Russell Collighan, Martin Griffin, Kamila Pytel, Zhuo Wang
-
Patent number: 9657068Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.Type: GrantFiled: February 15, 2011Date of Patent: May 23, 2017Assignee: Ultimovacs ASInventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
-
Patent number: 9644019Abstract: The present invention relates to the use of an Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) inhibitor for preventing and/or treating cardiac damage arising after an ischemic process followed by reperfusion. The authors of the present invention have observed that EMMPRIN expression increases in subjects who have suffered ischemia/reperfusion, ascertaining that an EMMPRIN inhibitor is capable of reducing the cardiac damage caused after ischemia followed by reperfusion, both in vitro and in vivo.Type: GrantFiled: December 1, 2011Date of Patent: May 9, 2017Inventors: Carlos Zaragoza Sánchez, Mónica Gómez Parrizas, Begoña Lavín Plaza, Carlos Tarín Cerezo
-
Patent number: 9636387Abstract: The present disclosure provides immunogenic compositions comprising the N-domain of carcinoembryonic antigen (CEA). These compositions are useful for inducing or enhancing an immune response, for inhibiting tumor cell growth and for treating cancer.Type: GrantFiled: August 18, 2014Date of Patent: May 2, 2017Assignee: Governing Council of the University of TorontoInventors: Aws Abdul-Wahid, Jean Gariépy
-
Patent number: 9632098Abstract: The present application provides compositions and methods useful for detecting and monitoring autoimmune diseases in a human subject. The methods comprise providing a moesin fragment for binding to an anti-moesin autoantibody and contacting the moesin fragment with a sample obtained from the human subject. The moesin fragment comprises the entire N-terminal FERM domain of a human moesin protein. The human subject has or is suspected of having an autoimmune disease such as connective tissue disease, systemic sclerosis, Sjogren's syndrome, or systemic lupus erythematosus.Type: GrantFiled: October 8, 2011Date of Patent: April 25, 2017Assignee: SHANGHAI KEXIN BIOTECH CO., LTD.Inventors: Xiaofeng Zeng, Yue Zhang, Zhinan Shou, Hua Mao, Hongbin Sun, Jie Qian, Yongjun Han, Weina Situ
-
Patent number: 9617304Abstract: The present invention relates to a novel endocytic motif, and in particular, to a fusion polypeptide including the motif represented by an amino acid sequence of SEQ ID NO. 1 and a protein transduction domain, a pharmaceutical composition for preventing or treating cancer including the same, and a method for treating cancer including the step of administering the composition. The present invention shows the effects of suppressing metastasis, infiltration, angiogenesis, and growth of cancer by specifically inhibiting c-Met endocytosis and effectively inhibiting HGF/c-Met signaling pathway associated with metastasis and growth of various types of cancer cells. Therefore, the present invention can be applied to an anticancer agent for various types of cancer.Type: GrantFiled: March 2, 2012Date of Patent: April 11, 2017Assignee: Korea Research Institute Of Bioscience And BiotechnologyInventors: Young Woo Park, Ki Won Jo, Kyu Won Cho, Ji Hyun Park, Soon Sil Hyun, Yun Jung Park
-
Patent number: 9612233Abstract: A previously unrecognized fundamental property of ?1Proteinase Inhibitor (?1PI) is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified ?1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with HIV-1 infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of ?1PI with its receptors, Human Leukocyte Elastase Cell Surface (HLECS) and Low Density Lipoprotein-Receptor Related Protein (LRP), influences the level of cells of different lineages. Genetic and proteolytic modification of ?1PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.Type: GrantFiled: November 22, 2011Date of Patent: April 4, 2017Assignees: The Institute for Human Genetics and BiochemistryInventor: Cynthia L. Bristow
-
Patent number: 9605251Abstract: Embodiments herein report compositions, methods and uses for inducing an innate immune response in a subject. Embodiments herein also generally report compositions, methods and uses for bacterial-derived peptides to induce an innate immune response in a subject having a bacterial or viral disorder and/or cancer. In certain embodiments, compositions herein concern derivatives of p60 protein of Listeria monocytogenes.Type: GrantFiled: November 10, 2010Date of Patent: March 28, 2017Assignee: NATIONAL JEWISH HEALTHInventors: Laurel L. Lenz, Rebecca L. Schmidt
-
Patent number: 9599621Abstract: Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing cancers, such as breast cancer, thyroid cancer, colorectal cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, or lung cancer, using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of folate receptor alpha in a sample derived from a subject and comparing this level with the level of folate receptor alpha in a control sample or reference sample.Type: GrantFiled: August 4, 2014Date of Patent: March 21, 2017Assignee: Eisai R&D Management Co., Ltd.Inventor: Daniel John O'Shannessy
-
Patent number: 9593166Abstract: This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin ? complexed with heparin and/or heparin-like structure (AT?H). These AT?H binding proteins can block the anti-coagulant activity of AT? to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.Type: GrantFiled: March 14, 2014Date of Patent: March 14, 2017Assignee: BAYER HEALTHCARE LLCInventors: Ye Jin, John E. Murphy, Terry Hermiston, Timothy Myles, Frank Dittmer, Michael Strerath, Uwe Gritzan
-
Patent number: 9587014Abstract: Provided are novel TAR DNA-binding proteins of 43 kDa (“TDP-43”)-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: October 26, 2012Date of Patent: March 7, 2017Assignees: Biogen International Neuroscience GmbH, University of ZürichInventors: Roger Nitsch, Christoph Hock, Maria Grazia Barenco Montrasio, Fabio Montrasio, Jan Grimm, Jean-Luc Baeriswyl, Paul Weinreb, Janaky Coomaraswamy, Omar Quintero-Monzon
-
Patent number: 9580704Abstract: A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as Pneumocystis spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.Type: GrantFiled: August 5, 2013Date of Patent: February 28, 2017Assignees: University of Pittsburgh—of the Commonwealth System of Higher Education, Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Jay K. Kolls, Michael Zheng, Karen Norris, Heather Kling
-
Patent number: 9579360Abstract: The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis.Type: GrantFiled: March 13, 2013Date of Patent: February 28, 2017Assignee: The Trustees of the University of PennsylvaniaInventors: John D. Lambris, George Hajishengallis
-
Patent number: 9561274Abstract: Embodiments provided herewith relate to methods and compositions for treating or preventing cancer. More particularly, several embodiments are drawn to treating or preventing malignant mesothelioma with antagonists of high-mobility group box 1 (HMGB1).Type: GrantFiled: June 7, 2012Date of Patent: February 7, 2017Assignee: UNIVERSITY OF HAWAIIInventors: Haining Yang, Michele Carbone, Marco E. Bianchi
-
Patent number: 9533003Abstract: It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.Type: GrantFiled: September 15, 2015Date of Patent: January 3, 2017Assignee: REPLICOR INC.Inventors: Michel Bazinet, Andrew Vaillant
-
Patent number: 9534027Abstract: In one aspect the present invention is directed to mutant Neutrophil Gelatinase Associated Lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.Type: GrantFiled: November 21, 2012Date of Patent: January 3, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jonathan Barasch, Andong Qiu
-
Patent number: 9526797Abstract: The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.Type: GrantFiled: August 7, 2013Date of Patent: December 27, 2016Assignee: Roche Glycart AGInventors: Christian Gerdes, Christian Klein, Valeria G. Nicolini, Pablo Umana
-
Patent number: 9518112Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: GrantFiled: March 6, 2013Date of Patent: December 13, 2016Assignee: Ludwig Institute for Cancer Research LTDInventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon